Drug Database
MY

MYJ-1633 (MYJ1633 / MYJ 1633)

✓ Approved

Immunisbio · Cell-based Therapies · Cell-based Therapies

What is MYJ-1633?

MYJ-1633 is a cell-based therapies developed by Immunisbio. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesMYJ1633, MYJ 1633
CompanyImmunisbio
Drug ClassCell-based Therapies
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, Immunisbio

Therapeutic Indications

MYJ-1633 is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Breast cancer✓ Approved

Related Research Articles

PubMedActa ophthalmologica2026-08-27

Evaluation of spatial distribution of initial marking strategy among inexperienced graders in diabetic retinopathy: A retrospective cross-sectional analysis.

Lowater Simon Joel Ellerup SJE, Núñez Andrea Blasi AB, Andersen Jakob Kristian Holm JKH, Dinesen Sebastian S et al.

Manual diabetic retinopathy (DR) grading may prefer certain regions and underestimate others. It is unclear if inexperienced graders' initial marking strategy reflects a specialist's marking pattern. By the virtual ocular learning platform (VIOLA), we evaluated if initial DR-lesion markings among inexperienced graders spatially corresponded to a specialist-based lesion map. We used retinal 6-field VIOLA images with at least 500 DR-lesion markings covering all DR-levels (0-4) according to the international clinical diabetic retinopathy (ICDR) scale. We divided images into quadrants and counted the initial three markings per lesion type, per image, per grader. A retinal specialist served reference for annotation of all DR-lesions. The primary outcome was difference in spatial distribution of DR-markings across quadrants relative to the reference, further characterised with spatial metrics. p-Value < 0.05 indicated statistical significance. Across 24 images, 97 graders marked 16 925 DR-lesions: 1633 microaneurysms (MA), 3228 haemorrhages, 1549 hard exudates (HE), 3081 cotton wool spots (CWS), 3844 intraretinal microvascular abnormalities (IRMA), 1832 new vessels (NV) and 1758 panretinal photocoagulation scars (PRP). A difference was observed across all lesion types (χ2-test, p < 0.001) relative to the reference lesion map. Most lesion types demonstrated high sensitivity, but low PPV, indicating a liberal marking approach. Distribution of initial markings from inexperienced graders spatially misaligns with a specialist-derived lesion map across all lesion types. As the ICDR-scale depends on identifying the most severe lesion type, systematically inconsistent search strategies may pose a risk for overlooking important lesions under time constraints. The results support the promotion of attention guiding during DR-training.

PMID 42657653
Read full article →
PubMedWater research2026-08-20

An overlooked resin composition effectively captures and releases various PFAS including challenging short-chain structures.

Kan Xiping X, Zhang Sizhuo S, Sarkar Swagotom S, Liu Jinyong J et al.

Capturing per- and polyfluoroalkyl substances (PFAS) from water via adsorption remains vital yet challenging due to the lack of effective sorbents with high affinity across the wide structural diversity, particularly the highly mobile short-chain PFAS. This limitation also challenges the performance of PFAS passive samplers. Here, we report a homemade anion exchange resin with polystyrene and triethylamine structures (PS-NEt3+) that is highly effective at capturing and releasing PFAS. PS-NEt3+outperformed commercial benchmarks in capturing various legacy and emerging PFAS across multiple matrices, exhibiting particularly high affinity for short-chain PFAS (>85% uptake) in the presence of inorganic competitors. PS-NEt3+also demonstrated superior uptake at a low sorbent dose (30 mg/L) for broad-spectrum PFAS, including unknown structures, in highly polluted scenarios with both inorganic and organic competitors. The 75/25 mixture of PS-NEt3+and a commercial resin further improves the capture of the 40 PFAS analytes in USEPA Method 1633. The mixture achieved a median regeneration recovery of 97% when eluted with methanol containing ammonium acetate. The high PFAS affinity and selectivity of the mixture make it an ideal receiving phase for passive samplers by overcoming the enduring challenge of limited uptake and early sorbent breakthrough in previous passive sampling studies. Furthermore, while resins with long or asymmetric amines have been considered superior for PFAS capture in previous studies, the surprisingly high performance of PS-NEt3+ challenges this prevailing assumption and opens new avenues for PFAS sorbent selection.

PMID 42624066
Read full article →
PubMedMaterials (Basel, Switzerland)2026-08-13

Sequential Carbide Precipitation During Tempering and Its Influence on Strength-Toughness Balance in 31CrMoNiNbV Secondary Hardening Martensitic Steel.

Zhao Fengping F, Mou Yanjie Y, Hu Jie J, Ma Xiying X et al.

The temperature-dependent carbide precipitation behavior and mechanical properties in 31CrMoNiNbV secondary hardening martensitic steel were investigated over a tempering temperature range of 200-650 °C. Sequential carbide precipitation behavior was characterized using scanning electron microscopy, electron backscatter diffraction and transmission electron microscopy, which was further correlated with tensile properties, hardness and low-temperature toughness. At the high tempering temperature of 580 °C, the investigated material achieved a well-balanced combination of tensile strength of 1633 MPa and total elongation of 15.1%, wherein tempering-induced M2C precipitation contributed to strength retention, while dislocation recovery and the formation of high-angle grain boundaries led to concurrent improvement in ductility and toughness. A predictive framework linking tempering temperature to carbides evolution and the resultant mechanical properties has been established for the investigated material, guiding the microstructural and heat treatment parameter design of ultra-high strength secondary hardening martensitic steels.

PMID 42590283
Read full article →
PubMedComputational biology and chemistry2026-07-31

A reproducible computational transcriptomic framework for cell-type-resolved fibroinflammatory-AKT remodeling in human heart failure.

Li YiMeng Y

Human heart failure involves multicellular transcriptional remodeling, but public transcriptomic studies often remain disconnected from cell-type localization and perturbational interpretation. We developed a reproducible computational workflow integrating human left-ventricular bulk transcriptomes, donor-level cell-type pseudobulk results from a human heart-failure single-cell/single-nucleus atlas, external snRNA-seq support, curated module scoring, focused ligand-receptor prioritization and LINCS/L1000 perturbational matching. Cross-cohort analysis identified 14,358 same-direction HF-associated genes, including 1633 replicated HF-up and 785 replicated HF-down genes. Donor-level pseudobulk analysis localized disease remodeling to cardiomyocyte, fibroblast and myeloid compartments. Activated fibroblast and inflammatory myeloid programs defined a fibroinflammatory remodeling axis connected to context-dependent AKT-associated transcriptional shifts. External snRNA-seq support was strongest for fibroblast activation and AKT-associated remodeling, with etiology-dependent heterogeneity across validation resources. L1000FWD screening prioritized safety-aware perturbational hypotheses, including glimepiride and simvastatin as interpretable candidates requiring experimental validation. This study provides a computational transcriptomic framework linking reproducible human HF signatures, cell-type-resolved fibroinflammatory remodeling and perturbational genomic prioritization without claiming drug efficacy or AKT causality.

PMID 42537336
Read full article →
PubMedEnvironmental science and pollution research international2026-07-21

Occurrence of per- and polyfluoroalkyl substances (PFAS) and their precursors in biosolids across 15 U.S. states.

Ye Xiayan X, Maroli Amith Sadananda AS, Chitthaluri Santhoshi S, Driver Erin M EM et al.

The US Environmental Protection Agency (EPA) draft sewage sludge risk assessment indicates that land application of biosolids containing as little as 1 ng/g of perfluorooctanoate (PFOA) or perfluorooctane sulfonate (PFOS) may exceed human health risk thresholds. This study provides updated measurements of per- and polyfluoroalkyl substances (PFAS) in US biosolids. Twenty-seven biosolid samples from 15 states were analyzed using EPA Method 1633 and the total oxidizable precursor (TOP) assay. Dominant PFAS included 5:3 fluorotelomer carboxylic acid (FTCA) (70.2 ± 84.7 ng/g), 7:3 FTCA (23.7 ± 43.7 ng/g), and PFOS (22.1 ± 45.2 ng/g), with total PFAS ranging from 2 to 807 ng/g, showing no correlation with sewer-shed population or industrial inputs. At one facility, PFAS increased from 17.3 ng/g in primary sludge to 150 ng/g in centrifuge cake, consistent with precursor transformation. TOP assay did not increase total PFAS levels but shifted the profile, with perfluoroalkyl carboxylic acids increasing and FTCAs and other precursors decreasing, likely reflecting incomplete transformation of precursors during wastewater and sludge treatment. These findings suggest that regulated PFAS will increase following land application due to transformation of precursors over time. Compared to the 2001 national sewage sludge survey samples, PFOA and PFOS declined by > 80%, yet remain at least one order of magnitude above 1 ng/g. Current study supports EPA's conclusion that land application of biosolids continues to pose potential human health risks.

PMID 42479291
Read full article →
PubMedNature communications2026-07-21

A longitudinal analysis of published clinical practice guidelines and their effect on disease burden.

Li Xialei X, Estau Dannya D, Huang Xiaoru X, Deng Fuhua F et al.

Clinical practice guidelines (CPGs) are intended to improve health and reduce disease burden, yet their global status and their association with disease burden remain unknown. This longitudinal ecological study analyzes the quantity and quality of CPGs and explores their associations with disease burden. From 1995 to 2023, 10,657 CPGs were published, with the number of CPGs in 2023 being 5.15 times the number of CPGs in 1995. Europe contributed 40.2% of all CPGs, while CPGs from Africa accounted for only 0.8% of and showed minimal growth. Treatment CPGs contributed the most (45.0%), while diagnosis CPGs showed the fastest growth. Prevention CPGs (8.4%) and nursing CPGs (5.3%) and rehabilitation CPGs were less common, with rehabilitation CPGs showing the slowest growth. The 3-year update rate of CPG is 23.8%. Quality assessment of 1633 CPGs using AGREE II revealed substantial variation across domains. Overall 37.8% CPGs achieved scores above 70% per domain, while the "applicability" domain had the lowest median score (36%). Cross-region CPGs and CPGs for neoplasms exhibited the highest AGREE II scores, with the median score exceeding 70% in 3/6 domains. In contrast, CPGs from Asia and CPGs for cardiovascular diseases did not exceed the 70% threshold in any domain. Neither the quantity nor the quality of CPGs was significantly associated with disease burden at the national level. In conclusion, this study reveals that the quantity of CPGs has increased over the past three decades, although geographic and thematic differences remain. Future opportunities for CPG development include improving the AGREE II scores and focusing on less represented areas including rehabilitation, nursing and prevention.

PMID 42477334
Read full article →

+938 more articles available with a free account

Sign up free to view all articles →

Ask about MYJ-1633